Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders clinical trials at UCSF
1 in progress, 1 open to new patients
A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
open to eligible people ages 18 years and up
To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.
San Francisco, California and other locations